Cinven is reviewing strategic options for laboratory-services company Synlab International GmbH including a potential sale, people with knowledge of the matter said.
The private equity firm has been speaking with potential advisers and could start a sale process early next year, the people said, asking not to be identified because the information is private. Cinven plans to seek a valuation of about 5.5 billion euros ($6 billion) including debt for Augsburg, Germany-based Synlab, one of the people said.
A sale of Synlab would likely attract other private equity firms, the people said. No final decision has been made, and Cinven could elect to keep the business, the people said. A spokeswoman for Cinven declined to comment, while Synlab didn’t answer phone calls seeking comment.
Cinven first invested in Synlab in June 2015, buying a majority stake from fellow private equity firm BC Partners for about 1.7 billion euros, Bloomberg News reported at the time. It combined the business with Labco SA, which it agreed to buy earlier that year for 1.2 billion euros.
Synlab, led by Chief Executive Officer Mathieu Floreani, also counts Novo A/S and Ontario Teachers’ Pension Plan as minority investors, according to its website. It operates across more than 40 countries, handling more than 500 million clinical tests annually, according to Synlab’s website.
Cinven also owns stakes in retailer Kurt Geiger and German drugmaker Stada Arzneimittel AG, according to its website.
The sale plan comes at a time when Cinven’s rival Apax Partners is also weighing a sale of diagnostic services business Unilabs. The buyout firm is working with advisers at Rothschild & Co. to look at options for the business, people familiar with the matter said last week.
Source: Bloomberg
Can’t stop reading? Read more
L’Occitane weighs US IPO less than two years after €6bn take-private
L’Occitane weighs US IPO less than two years after €6bn take-private L’Occitane Groupe is considering a return to public markets through a potential US initial public offering, less than two years after its billionaire owner took the skincare group private, according...
Advent tests exit window with €3bn sale of Irca
Advent tests exit window with €3bn sale of Irca Advent International is preparing to bring Italian industrial confectionery group Irca to market in a sale that could value the business at about €3bn, says Bloomberg. UBS and Rothschild are advising on the process,...
KKR set to top $20bn target for flagship Americas buyout fund
KKR set to top $20bn target for flagship Americas buyout fund KKR is on track to surpass the $20bn target for its flagship North America buyout fund, underlining the firm’s fundraising strength as many peers struggle to hit goals, according to Bloomberg. People...